EPO and obesity disorder: Tsuma et al. demonstrated that 4-week intraperitoneal injection of EPO and a long-acting erythropoiesis-stimulating agent darbepoetin alfa ameliorated glucose tolerance and insulin resistance in mice with high-fat diet-induced obesity [22].